For a Healio article highlighting the FDA approval of sotatercept, a drug to treat pulmonary arterial hypertension (PAH), Mario Naranjo-Tovar, MD, MHS, Assistant Professor of Thoracic Medicine & Surgery at the Lewis Katz School of Medicine at Temple University, provided perspective on what this decision means for patients, as well as its impact on the future of care for PAH.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH